Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects

Annals of Hepatology

Volumn 10, Issue 3, 2011, Pages 327-332

  Ho, Martin T ^a   Kelly, Edward J ^a   Bodor, Miklos ^a,b   Bui, Tot ^a,b   Kowdley, Kris V ^a,c   Ho, Rodney J Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

CYP450 enzyme; Genetic variant; Genotype; Hepatitis; Phenotype

Indexed keywords

CYTOCHROME P450 2D6;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CYTOCHROME P450 2D6 GENE; DNA SEQUENCE; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE;

EID: 79959420964     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31545-5     Document Type: Article

References (13)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286(5439): 487-91.
2. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45(6): 889-904.
3. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, Eichelbaum M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11(7): 573-85.
4. Bock KW, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994; 4(4): 209-18.
5. Griese EU, et al. Assessment of the predictive power of genotypes for the invivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8(1): 15-26.
6. Sachse C, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60(2): 284-95.
7. McConnachie L, Bodor M, Kowdley K, Levy A, Tung B, Thummel K, et al. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate. Clin Pharmacol Ther 2004; 75(4): 282-97.
8. McConnachie LA, Bodor M, Phillips B, Kelly EJ, Shen DD, Ho RJ. An RT-PCR-based Strategy to Estimate Full-Length CYP2D6 mRNA Copy Number. Genetic Testing 2004; 8(3): 313-8.
9. Day-Gaunt TR, Rodríguez S, Day IN. Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'Cubex'. BMC Bioinformat 2007; 8: 428.
10. Gaedigk A, et al. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem 2003; 49(6 Pt.): P1008-P1011.
11. Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Spire C, Lafitte JJ, Meyer UA, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7(3): 193-202.
12. Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 2004; 76(2): 128-38.
13. Gaedigk A, Ryder DL, Bradford LD, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem 2003; 49(6 Pt.1): 1008-11.